Literature DB >> 3538487

Value of serial peak expiratory flow measurements in assessing treatment response in chronic airflow limitation.

D M Mitchell, P Gildeh, A H Dimond, J V Collins.   

Abstract

A double blind, randomised, placebo controlled, crossover trial of prednisolone (40 mg/day for 14 days) was carried out in 33 patients with chronic airflow limitation (mean age 62 years, mean FEV1 1.01 litres, mean FEV1/FVC ratio 44%), to assess the value of serial peak expiratory flow (PEF) measurements, taken five times daily in evaluating treatment response by comparison with other objective measurements and with measurements of symptoms. The mean serial PEF after a one week run in period was 189 1 min-1, during the second week of placebo 193 1 min-1, and during the second week on prednisolone 231 1 min-1. The difference in mean PEF values between placebo and prednisolone was significant (p less than 0.01). With regard to the response to steroids of the individual patients, 13 of the 33 had a detectable trend of improvement on visual inspection of serial PEF measurements during prednisolone treatment but only one during placebo administration. Of all the objective measurements made after the run in and after each treatment phase (12 minute walking distance, FEV1, forced vital capacity (FVC), serial PEF), the serial PEF chart provided the best discrimination between placebo and prednisolone treatment. There was no statistically significant association between steroid induced improvement in serial PEF measurements and in breathlessness, partly because of placebo improvements in symptoms in those who had no improvement in serial PEF values. This study indicates the importance of making objective measurements to identify a genuine steroid response rather than relying on symptomatic improvement alone. The best simple measurement to make is serial PEF during steroid trials. This is more sensitive in detecting a steroid response than are the 12 minute walking distance, FEV1, or FVC, and is also less likely than these measurements to show spurious placebo responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3538487      PMCID: PMC460405          DOI: 10.1136/thx.41.8.606

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population.

Authors:  C M FLETCHER; P C ELMES; A S FAIRBAIRN; C H WOOD
Journal:  Br Med J       Date:  1959-08-29

2.  On observing patterns of airflow obstruction in chronic asthma.

Authors:  M Turner-Warwick
Journal:  Br J Dis Chest       Date:  1977-04

Review 3.  The pulmonary clock.

Authors:  M R Hetzel
Journal:  Thorax       Date:  1981-07       Impact factor: 9.139

4.  An evaluation of cusum analysis in asthma.

Authors:  D M Mitchell; J V Collins; J Morley
Journal:  Br J Dis Chest       Date:  1980-04

5.  A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response.

Authors:  S M Harding; S Freedman
Journal:  Thorax       Date:  1978-04       Impact factor: 9.139

Review 6.  Corticosteroids in chronic bronchitis and pulmonary emphysema.

Authors:  S A Sahn
Journal:  Chest       Date:  1978-03       Impact factor: 9.410

7.  Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease.

Authors:  C R McGavin; M Artvinli; H Naoe; G J McHardy
Journal:  Br Med J       Date:  1978-07-22

8.  Recovery of plasma corticotrophin and cortisol levels after three-week course of prednisolone.

Authors:  J Webb; T J Clark
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

9.  Steroid response in stable chronic obstructive pulmonary disease.

Authors:  L A Mendella; J Manfreda; C P Warren; N R Anthonisen
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

10.  Diurnal variation in airflow obstruction in chronic bronchitis.

Authors:  K D Dawkins; M F Muers
Journal:  Thorax       Date:  1981-08       Impact factor: 9.139

View more
  8 in total

1.  The influence of social factors on the control of asthma.

Authors:  C K Connolly; N S Chan; R J Prescott
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

2.  Falsely high peak expiratory flow readings due to acceleration in the mouth.

Authors:  C K Connolly
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

3.  Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction.

Authors:  C A Kelly; G J Gibson
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

Review 4.  The need for standardisation of peak flow charts.

Authors:  H K Reddel; S D Vincent; J Civitico
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

5.  A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group.

Authors:  J A van Noord; T A Bantje; M E Eland; L Korducki; P J Cornelissen
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

6.  Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate.

Authors:  D C Weir; R I Gove; A S Robertson; P S Burge
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

7.  Time course of response to oral and inhaled corticosteroids in non-asthmatic chronic airflow obstruction.

Authors:  D C Weir; A S Robertson; R I Gove; P S Burge
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

8.  Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group.

Authors: 
Journal:  CMAJ       Date:  1992-08-15       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.